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Abstract: We retrospectively evaluated predictive prognostic factors in 73 cats with vaccine-associated
sarcoma given postsurgical curative (n=46, most with clean margins) or coarse fractionated radiother-
apy (n=27, most with either macroscopic disease or dirty margins). The former animals displayed a
median survival of 43 months and a median progression free interval (PFI) of 37 months, the latter
reached a median survival of 24 months and a median PFI of 10 months. In cats undergoing coarse
fractionated therapy, factors predictive of a better outcome included lack of visible mass (n=10) as
opposed to macroscopic disease (n=17, survival: 30 vs. 7 months, P=0.025; PFI: 20 vs. 4 months,
P=0.01), adjuvant chemotherapy for gross disease (n=5/17, survival: 29 vs. 5 months, P=0.04) and
a smaller number of surgeries preceding radiation therapy (Coeff=0.41, P=0.03). The Ki67-index was
not predictive for survival. We concluded that postsurgical curative and coarse fractionated radiother-
apy are both effective legitimate options for managing vaccine-associated sarcomas. Einleitung: Bei
dem felinen vakzin-assoziierten Sarkom handelt es sich um einen extrem invasiven und oftmals schnell
wachsenden Tumor. In früheren Studien über humane und canine Weichteilsarkome konnte aufgezeigt
werden, dass eine hohe, zelluläre Proliferationsrate mit einem biologisch aggressiveren Tumorverhalten
korreliert. Methode: Retrospektiv evaluierten wir prädiktive prognostische Faktoren anhand von 73
Katzen, die an einem felinen vakzin-assoziierten Sarkom erkrankten. Die Behandlung umfasste entweder
eine postchirurgische kurative oder palliative Bestrahlung. Zudem ermittelten wir die Proliferationsrate
bei felinen vakzin-assoziierten Sarkomen mittels Ki67 Immunohistochemie und stellten diese Ergebnisse
in Bezug zum Behandlungserfolg, in der Annahme dass ein hoher Ki67-Index mit einem schlechten Thera-
pieergebnis, also einem kurzen Rezidiv-freien Intervall einhergeht. Resultate: Die mittlere Überlebenszeit
für die 46 kurativ behandelte Katzen (Tumorexzision und anschliessende, definitive Bestrahlung) betrug
43 Monate. Das mittlere Rezidiv-freie Intervall betrug für diese Patienten 37 Monate. Insgesamt hat-
ten palliativ behandelte Katzen (n=27) eine mittlere Überlebenszeit von 24 Monaten und ein mittleres
Rezidiv-freies Intervall von 10 Monaten. Allerdings war die mittlere Überlebenszeit für Katzen, deren
sichtbare Tumormasse palliativ bestrahlt wurde nur 7 Monate (mittleres Rezidiv-freies Intervall 4 Monate)
und damit signifikant kürzer, als wenn diese Tumormasse vor der palliativen Bestrahlung exzidiert wurde
(mittlere Überlebenszeit 30 Monate; mittleres Rezidiv-freies Intervall 20 Monate). Sobald aber nach der
palliativen Bestrahlung eines sichtbaren Tumors noch Doxorubizin verabreicht wurde, konnte die mittlere
Überlebenszeit signifikant verlängert werden (29 Monate; n=5). Aufgrund der zu geringen Anzahl an
Patienten, konnte der zusätzliche Zeitgewinn für Katzen, die nach einer Operation palliativ bestrahlt
wurden und Chemotherapie bekommen haben, nicht evaluiert werden. Erstaunlicherweise wurde das
Rezidiv-freie Intervall bei kurartiv behandelten Katzen tendenziell länger, sobald > 10% der Zellen Ki67
positiv waren (P=0.08). Bei palliativ behandelten Katzen wurde es signifikant länger, sobald > 20%
der neoplastisch veränderten Zellen Ki67 positiv waren (P=0.015); allerdings wurden die palliativ be-
handelten Tiere äusserst unterschiedlich therapiert, sodass keine echte Schlussfolgerung daraus gezogen
werden sollte. Fazit: Das Ki67-Index scheint bei felinen vakzine-assoziierten Sarkomen weder für die
Überlebenszeit noch für das Rezidiv-freie Intervall ein klarer prognostischer Parameter zu sein.
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 Introduction 
 In the US cat population, feline vaccine-associated 
sarcomas have an incidence of approximately 
1/10  000 1 – 3 to 1/1000 4 cats. One study in Germany 
estimated the incidence in this country to 1 case 
per 1000 cats. 5 Vaccine-associated sarcomas 
account for about 40% of all feline skin tumours 6 – 8 
and are the most frequent skin tumour in this 
species. 5 
 Although the pathogenesis of vaccine-associated 
sarcoma has not been deﬁ nitively elucidated, it is 
 *  This study was conducted in the context of a doctoral 
thesis (C.  E.). 
 A retrospective analysis of radiation 
therapy for the treatment of feline 
vaccine-associated sarcoma * 
 C.  Eckstein 1 ,  F.  Guscetti 2 ,  M.  Roos 3 ,  J.  Martín de las Mulas 4 ,  B.  Kaser-Hotz 1 
 and  C. Rohrer  Bley 1 
 1  Diagnostic Imaging and Radio-Oncology, Vetsuisse Faculty University of Zurich, Zurich, Switzerland 
 2  Institute of Veterinary Pathology, Vetsuisse Faculty University of Zurich, Zurich, Switzerland 
 3  Biostatistics Unit, Institute for Social and Preventive Medicine, University of Zurich, Zurich, Switzerland 
 4  Department of Comparative Pathology, Veterinary School, University of Córdoba, Campus de Rabanales, 
Córdoba, Spain 
 Abstract 
 We retrospectively evaluated predictive prognostic factors in 73 cats with vaccine-associated 
sarcoma given postsurgical curative ( n  =  46, most with clean margins) or coarse fractionated 
radiotherapy ( n  =  27, most with either macroscopic disease or dirty margins). The former animals 
displayed a median survival of 43  months and a median progression free interval (PFI) of 37  months, 
the latter reached a median survival of 24  months and a median PFI of 10  months. In cats undergoing 
coarse fractionated therapy, factors predictive of a better outcome included lack of visible mass 
( n  =  10) as opposed to macroscopic disease ( n  =  17, survival: 30 versus 7  months,  P  =  0.025; PFI: 20 
versus 4  months,  P  =  0.01), adjuvant chemotherapy for gross disease ( n  =  5/17, survival: 29 versus 
5  months,  P  =  0.04) and a smaller number of surgeries preceding radiation therapy (coeff  =  0.41, 
 P  =  0.03). The Ki67 index was not predictive for survival. We concluded that postsurgical curative and 
coarse fractionated radiotherapy are effective legitimate options for managing vaccine-associated 
sarcomas. 
believed to involve chronic local inﬂ ammation, 
which has been associated with the adjuvant in the 
vaccines 1,2,9,10 and age-related immunodeﬁ ciency. 11 
In addition, there have also been single reports of 
sarcoma development after the injection of other 
agents like methylprednisolone or penicillin, 12 and 
lufenuron 13 ; even suture material was associated 
with the formation of ﬁ brosarcomas. 14 
 Vaccine-associated sarcomas are highly inva-
sive and often rapidly growing neoplasms. The 
evolution of treatment from single 15 – 17 to multi-
modality 18 – 21 therapy has resulted in longer pro-
gression free interval (PFI) and survival time. 
For example, in cats treated with surgery only, 
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the median survival time was 576  days, 17 and in 
cats treated with chemotherapy only, there was a 
50% overall response rate and the median survival of 
the responders was 242  days. 16 In contrast, in cats 
undergoing multimodality treatment, radiation ther-
apy prior to surgery resulted in a median survival 
time of 600  days, 20 and when radiation therapy was 
applied after surgery, the median survival time was 
730  days. 18 But despite the combination of aggres-
sive surgery and curative radiation therapy, treat-
ment still fails in many patients. For this reason and 
because of its high costs and time requirements, cu-
rative radiation therapy is not always an acceptable 
option for the owners. A coarse fractionation pro-
tocol was designed as an alternative. To our knowl-
edge, such a protocol has not been published so far 
for the therapy of vaccine-associated sarcomas. 
 Vaccine-associated sarcomas have histological 
characteristics considered either unique 22 or sug-
gestive for this diagnosis 23 as opposed to sarcomas 
not associated with vaccination. In addition to a 
broad spectrum of histological types, they usually 
display peripheral inﬂ ammation consisting pre-
dominantly of lymphocytes and smaller number of 
plasma cells usually located around blood vessels. 24 
The presence of peripheral aggregates of macro-
phages containing intracytoplasmic globular grey –
 brown material, which has been shown to contain 
aluminium, supports the diagnosis of vaccine-
associated sarcoma. 25 
 Both histological features of soft tissue sarcomas 
and tumour proliferation index have been exam-
ined in human and animal tumours. High tumour 
proliferation has been shown to correlate with 
aggressive behaviour in soft tissue sarcomas in 
humans. 26 – 30 Among several different possibilities 
to assess cell proliferation, the Ki67 index has 
been proposed as an intrinsic cell kinetic parameter 
with a potential prognostic value in human soft 
tissue sarcomas 26 – 30 and in canine tumours of 
various origins. 31 – 37 In cats, the Ki67 index was 
determined in apocrine sweat gland tumours, 38 
melanocytic tumours, 39 squamous cell carcino-
mas, 40 lymphoma 41 and mammary tumours. 42 
One paper reports determination of the Ki67 
index in feline vaccine-associated sarcomas. 43 No 
signiﬁ cant differences were found among the 
average proliferation rates determined through 
measurements of the Ki67 reactivity at the 
tumour periphery among tumours of different his-
tological grade. 43 In addition, no signiﬁ cant differ-
ence was found between the proliferation index at 
the periphery and in central areas of the tumours. 
To our knowledge, the prognostic value of the Ki67 
index has not yet been investigated in feline 
vaccine-associated sarcomas. Immunohistochem-
istry for Ki67 is well established for formalin-ﬁ xed, 
parafﬁ n-embedded tissues. 43–45 Therefore, it is well 
suited to perform retrospective studies. 
 The two major aims of this retrospective study 
were (1) to evaluate the survival and PFI of curative 
versus coarse fractionated radiotherapy patients; 
and (2) to determine the growth fraction of vaccine-
associated sarcomas by Ki67 immunohistochemis-
try and the predictive value of the Ki67-labelling 
index. Additional variables assessed in the outcome 
analysis included demographical and clinical char-
acteristics as well as histological parameters. 
 Materials and methods 
 Patients 
 Medical records of all cats with histologically 
conﬁ rmed soft tissue sarcomas that underwent 
radiation therapy at the section of Diagnostic 
Imaging and Radiation Oncology at the Vetsuisse 
Faculty, University of Zurich, Switzerland, between 
1996 and 2005 were reviewed. Only cats in which 
the tumour was determined to be vaccine associ-
ated on the basis of vaccination history and tumour 
location were included in the study. Thus, cats with 
sarcomas in locations not associated with vaccina-
tion (i.e. head, tail, oral cavity and distal regions of 
the limbs) were excluded. 
 The diagnostic work up in the selected cats 
included a physical examination, a complete blood 
count and a chemistry panel to evaluate the general 
health status and two lateral thoracic radiographs 
to search for distant metastases. Additional labora-
tory and diagnostic tests as well as further imaging 
procedures were conducted as needed. Tumour 
location, presence and size of gross tumour or of a 
scar as well as the number of previous excisions 
were gathered from the medical records for statistical 
analysis. 
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 Radiation therapy 
 All cats were treated with external-beam megavoltage 
radiation. Radiation was delivered with a linear ac-
celerator (Dynaray LA20; VARIAN, Zug, Switzerland) 
using 9 – 16  MeV electrons. Treatment plans were 
calculated manually, and the ﬁ eld dimensions were 
adjusted to enclose at least a 3-cm margin of pre-
sumed normal tissue adjacent to the tumour or the 
scar. Dose distribution was improved by using 
tissue-equivalent bolus material. Therapy plans 
were designed to maximally spare the spinal cord as 
well as the thoracic and abdominal organs. 
 Irradiation was delivered with either a curative 
intent or a coarse fractionation protocol. The pre-
scribed total dose for curative radiation therapy was 
either 48  Gy (12  ×  4.0  Gy, delivered on a Monday –
 Tuesday – Thursday – Friday schedule) or 45  Gy 
(9  ×  5.0  Gy, delivered on a Monday – Wednesday –
 Friday schedule). The standard protocol for coarse 
fractionation consisted of four fractions of 8.0  Gy 
each administered once a week. Criteria shifting 
decision towards the use of the coarse fractionation 
protocol included the presence of gross, non-
resectable tumour, incomplete tumour excision and 
concurrent medical problems. Surgical excision was 
considered  ‘ wide ’ if there was >1  cm of non-neo-
plastic tissue around the tumour as determined by 
histological examination. If tumour cells did not ex-
tend to the excision margin, yet were within 1  cm of 
the margin, tumour excision was then called  ‘ clean 
but close ’ . In cases with either  ‘ wide ’ or  ‘ clean but 
close ’ margins, excision was considered  ‘ complete ’ , 
and for these cats, curative radiation therapy was pro-
posed to the cat ’ s owner. When neoplastic cells ex-
tended to the cut surface, the margins were considered 
 ‘ dirty ’ and surgical excision was considered  ‘ incom-
plete ’ . In these cats, a coarse fractionation protocol 
was recommended. However, the ﬁ nal decision on 
which protocol to follow was left to the owner, which 
entails heterogeneity in the two treatment groups 
because of deviations from our recommendations. In 
some cases, the margins had not been evaluated. 
These excisions were classiﬁ ed as  ‘ not assessable ’ , and 
the decision towards one of the protocols was made 
on other variables, i.e. age, health, size of the scar, etc. 
Chemotherapy was recommended for all cats 
receiving coarse fractionated radiotherapy. 
 For radiation therapy, cats were anaesthetized 
with either propofol (Propofol 1% Fresenius ® ; 
Fresenius Kabi AG, Stans, Switzerland) administered 
as the sole anaesthetic agent or a combination of 
propofol/midazolam (Dormicum ® ; Roche Pharma 
AG, Reinach, Switzerland) or midazolam/ketamin 
(Narketan ® 10; Vetoquinol AG, Belp, Switzerland) 
administered to effect. Oxygen was provided by 
mask during radiation. 
 Follow-up evaluation 
 During the recheck examination 3  weeks after 
completion of radiotherapy, patients were as-
sessed for acute side-effects. Thereafter, the 
owners were instructed to consult for assessment 
of response to therapy at 3-month intervals. 
These rechecks included regular thoracic radiog-
raphy to evaluate for gross pulmonary metasta-
sis. For cats that were not re-evaluated at the 
Vetsuisse Faculty, around the time of data 
analysis (20 September 2005), the referring 
veterinarians and owners were queried by tele-
phone interview about general health and tumour 
status and in case of death if the cause was tu-
mour related or unrelated. No necropsies were 
performed. 
 PFI was deﬁ ned as the time from the start of ra-
diotherapy at the Vetsuisse Faculty in Zurich to the 
onset of local recurrence or progression of gross 
disease or development of distant metastasis. Sur-
vival time was deﬁ ned as the time between the start 
of radiotherapy and the date of death or the date of 
last follow-up or the date of data analysis for ani-
mals still alive. In animals with gross disease, re-
sponse to treatment was deﬁ ned as follows: a 
 ‘ complete response ’ was deﬁ ned as disappearance 
of all measurable disease based on physical exami-
nation.  ‘ Partial remission ’ indicated a tumour size 
reduction by  ³ 50%, with no new lesions develop-
ing.  ‘ Stable disease ’ was deﬁ ned as less than 50% 
size decrease or up to 25% increase, and  ‘ progres-
sive disease ’ indicated an increase in tumour mea-
surements of  ³ 25% or the development of new 
lesions or metastasis. At the occurrence of progres-
sive disease, additional therapy was offered to all 
patients, regardless of the initial treatment. The 
options offered included chemotherapy, a second 
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round of radiation therapy, ancillary surgery or a 
combination of these modalities. 
 Histopathological reassessment 
 Parafﬁ n blocks of the cases were obtained when 
available either from the archives of the Institute of 
Veterinary Pathology Zurich or from external di-
agnostic laboratories. Histopathology was per-
formed (by F.  G. and C.  E.) using haematoxylin 
and eosin-stained sections. Depending on the pre-
dominant cellular morphology, the tumours were 
classiﬁ ed as ﬁ brocytic (indicating a spindle cell 
morphology), histiocytic or mixed cell type, refer-
ring to a mixed ﬁ brocytic – histiocytic variant 
( Fig.  1 ). Tumour grade based on cellular differenti-
ation, presence and extension of necrosis within 
the neoplasm and mitotic rate were assessed as 
described by Couto  et al. 43 ( Table  1 ). This scheme 
was originally designed for the grading of soft 
tissue sarcomas in humans 30 and later adapted for 
veterinary medicine by Kuntz  et al. 46 
 Tissue array construction and 
immunohistochemistry 
 The parafﬁ n blocks obtained were used for tissue 
array construction. During histopathological anal-
ysis, areas with viable tumour tissue and areas with 
necrosis or with marked inﬂ ammatory inﬁ ltrates 
were labelled on each corresponding tissue section. 
Labelling was used to select tumour regions in the 
parafﬁ n blocks devoid of necrosis and marked 
inﬂ ammation for tissue array construction. Tissue 
cores (0.6  mm in diameter) were taken randomly 
from the preselected tumour areas; the number of 
cores taken per tumour ranged from 6 to 50, with a 
mean of 22. In the ﬁ rst step, between 6 and 12 cores 
  
 Figure  1.  Histomorphological subtypes and Ki67 immunohistochemistry of vaccine-associated sarcomas. A: example of 
tumour with predominant ﬁ brocytic morphology, hematoxylin and eosin stain. B: example of tumour with predominant 
histocytic morphology, hematoxylin and eosin stain. C: Ki67 immunohistochemistry of same tumour as in A; positive 
nuclei are darkly stained. D: Ki67 immunohistochemistry of same tumour as in B; positive nuclei are darkly stained. 
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were taken depending on the cellular density of 
each particular tumour tissue. Further cores were 
added later as needed to reach the minimal num-
ber of cells required for the Ki67 counts. Sections 
from the arrays were labelled immunohistochemi-
cally with antibodies speciﬁ c for T or B lymphocytes 
and for Ki67. 
 CD3 and CD79alpha 
 Immunohistochemistry with antibodies anti-CD3 
(for T lymphocytes) and anti-CD79alpha (for B 
lymphocytes) was used to exclude tissue areas with 
marked inﬂ ammatory inﬁ ltrates for the subsequent 
Ki67 assessment. This was performed to avoid 
erroneous counting of lymphatic cell nuclei, which 
was deemed to be an issue especially in tumour 
cores with a transversal plane of section. Hence, 
only areas with less than 10% positive cells for CD3 
or CD79alpha were used to determine the numbers 
of Ki67-positive cells. For the detection of CD3-
positive cells, a polyclonal anti-human pan T-cell 
antibody (catalogue number A0452; Dako 
Cytomation, Zug, Switzerland) was used. CD79alpha-
positive cells were labelled using a monoclonal 
anti-human pan B-cell antibody (catalogue number 
M7051; Dako). In both cases, sections were pre-
treated for 20  min in a pressure cooker at 98  °C in 
basic buffer (pH  =  8; catalogue number S2367; 
Dako). Endogenous peroxidase was inactivated by 
immersing the slides in peroxidase-blocking solu-
tion (Dako) for 10  min at room temperature. The 
anti-CD3 antibody was diluted 1:250, the anti-
CD79alpha antibody was diluted 1:300 and both 
antibodies were incubated for 1  h at room temper-
ature. For detection of the primary antibody, the 
Detection Kit (Dako) was applied according to the 
manufacturer ’ s instructions. The reaction was 
visualized by means of an AEC chromogen (Dako), 
and the slides were counterstained with hemalum. 
A lymph node from a cat was used as a positive 
control, and for negative controls, incubation of 
the primary antibody was omitted. 
 Ki67 index 
 The sections were labelled for Ki67 (monoclonal 
antibody anti-human Ki67, clone MIB-1, catalogue 
number M7240; Dako) using a protocol previously 
described for cat tissues by Melzer  et al. 40 Positive 
and negative tissues included into the arrays com-
prised cores bearing a squamous cell carcinoma 
and normal skin including hair follicles and musculi 
arrectores pilorum. The percentage of positive 
tumour cells was determined by computer-assisted 
manual counting. All slides were scanned with a 
ScanScope (Aperio Technologies, Inc., Vista, CA, 
USA), and snapshots of randomly chosen regions 
of each core were taken at 40× magniﬁ cation using 
the computer program  ‘ Aperio ImageScope ’ ver-
sion 7.1.32.1024 (Aperio Technologies, Inc.). A 
sufﬁ cient number of ﬁ elds were photographed to 
allow a minimum of 700 neoplastic cells per 
tumour to be counted. A minimum number of six 
cores were assessed for each tumour. The number 
of cells counted per ﬁ eld varied depending on the 
cellular density of each tumour ( Fig.  1 ). Additional 
cores were added when needed to reach the minimal 
number of cells to be counted as indicated above. 
The Ki67 index was deﬁ ned as the percentage of 
Ki67-positive tumour cells and was determined by 
dividing the number of positive cells by the total 
 Table  1.  Criteria and results of histological grading ( n  =  55) a 
 Score 
 Cellular 
differentiation  n  (%)  Necrosis  n  (%) 
 Number of mitotic ﬁ gures 
per 10 hpf  n  (%) 
1 Resembles normal adult 
 mesenchymal tissue
0 (0) None 8 (15) 0 – 9 19 (35) 
2 Speciﬁ c histological type 40 (73) <50% 41 (75) 10 – 19 13 (24) 
3 Undifferentiated 15 (27) >50% 6 (11)  ³ 20 23 (42) 
 hpf, High power ﬁ elds. 
 a Grade is the result of cumulative scoring by adding the individual scores for cellular differentiation, necrosis and mitotic rate. 
The study material was graded as follows: grade I (cumulative score of 3 or 4):  n  =  2 (3%); grade II (cumulative score of 5 or 6): 
 n  =  25 (46%); grade III (cumulative score of 7 – 9):  n  =  28 (51%). 
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number of positive and negative tumour cells, 
multiplied by 100. 
 Statistical analysis 
 To calculate the PFI local recurrence, progression 
of gross disease and distant metastasis were deﬁ ned 
as event. Animals that did not experience a PFI 
event by the time of data analysis or at last follow-
up were censored. In the survival analysis, deaths 
attributable to or likely attributable to disease pro-
gression were considered events. Cats still alive at 
the time of data evaluation or deceased because of 
a tumour-unrelated cause or lost to follow-up were 
censored in the survival analysis. Median PFI and 
survival were compared with respect to demo-
graphical and clinical characteristics (i.e. age, sex, 
breed, weight, vaccination history, tumour loca-
tion, radiation protocol, total dose (Gy), tumour 
margins, number of surgeries before radiation 
therapy, adjuvant chemotherapy and response after 
initial therapy) and histological parameters (i.e. 
cell type, grade, mitotic rate, amount of necrosis in 
the tumour, overall differentiation of the tumour 
tissue, presence of multinucleated giant cells and 
percentage of Ki67-positive cells) by the Kaplan –
 Meier method together with logrank (Mantel – Cox) 
and Breslow – Gehan – Wilcoxon tests and univariate 
proportional hazards analysis. Because of the low 
number of grade I tumours in this study, for statis-
tical analysis, it was necessary to dichotomize the 
cases into a low-grade group (histological grades I 
and II) and a high-grade group (histological grade 
III). To develop multiple Cox regression models, 
predictors with a  P  <  0.1 in the univariate analysis 
or otherwise relevant were included in the back-
ward Cox regression. The resulting ﬁ nal multiple 
models were as follows. For the evaluation of Ki67 
in association with survival and PFI, three different 
predictors were considered: ﬁ rst, Ki67 was exam-
ined in a continuous form; second, a binary (0/1) 
variable with a cut-off by the median (10% positive 
cells) was computed, and third, a binary (0/1) variable 
with a cut-off of 20% (positive cells) suggested by 
the receiver operating characteristics (ROC) analy-
sis was evaluated. The inﬂ uence of the different 
tumour and patient characteristics as listed above 
on descriptors of proliferation was evaluated using 
the Wilcoxon rank test and the Fisher ’ s exact test. 
For statistical analysis, StatView 5.0.1 (SAS Institute 
Inc., Cary, NC, USA) and SPSS 13.0. (SPSS Inc., 
Chicago, IL, USA) were used. Throughout the 
study, the results of statistical analysis with  P  value 
smaller than 5% were considered to be signiﬁ cant. 
 Results 
 Demographics 
 Of the 73 cats included in this study, 29 (40%) were 
neutered males and 44 (60%) were spayed females. 
The age of the cats ranged from 4.0 to 18.0  years, 
with both a mean and median age of 9.0  years. 
Breeds represented included 66 Domestic Short 
Hairs, 4 Persian, 1 Main Coon, 1 Oriental Shorthair 
and 1 Turkish Angora. Weight ranged from 3.0 to 
7.9  kg, with a mean of 4.9  kg. All 73 cats were vacci-
nated at least once in their life against feline viral 
panleucopenia/rhinothracheitis/calicivirus and/or 
feline leukaemia virus (FeLV), and/or rabies. Primary 
tumour location included the neck/scapular/inter-
scapular region (59%), the thoracic and abdominal 
wall (23%) or the ﬂ ank/lumbar region (18%). 
 All 73 patients were followed up to death or to 
the time of data analysis except for 1 cat that was 
lost to follow-up. Thirty-two patients died or were 
killed because of tumour-related disease, 24 be-
cause of tumour-unrelated disease (i.e. car acci-
dent, heart failure, pulmonary oedema, pleural 
effusion, liver tumour, renal failure, diabetes mel-
litus, ileus, ascites, etc.), and in 3 cases, the cause of 
death could not be assessed. Metastases were not 
observed in any of the cats during or after therapy. 
 Radiation therapy 
 In this and in the following paragraphs, details per-
taining to clinical characteristics and to therapeutic 
modalities of the cats examined in the study are given. 
The most important information is summarized 
in  Table  2 . 
 A total of 46 cats received curative radiation 
therapy. In three of these cats, there was a visible 
mass. Response was complete in one cat, which 
underwent surgery after radiation therapy. Stable 
disease was observed in the other two cats. A total 
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of 27 cats were treated with the coarse fractionation 
protocol. The majority (17/27, 63%) of these cats 
were presented with macroscopic disease. Of those 
17 patients, two had a complete response, which al-
lowed postradiation surgical excision, seven had a 
partial remission, seven had stable disease and one 
cat had progressive disease during radiation therapy. 
 Adverse effects of radiation were reported to be 
mild and self-limiting with only dry desquamation, 
alopecia and depigmentation of the irradiated ﬁ eld. 
Negligible differences in intensity of side-effects 
between curatively treated cats and those receiving 
coarse fractionated therapy were found, but the 
former animals appeared to have side-effects more 
frequently. There were no differences in the ad-
verse effects between cats that received concurrent 
chemotherapy and those that had radiation ther-
apy as a sole treatment modality. 
 Surgery 
 Of all 46 cats receiving curative radiation therapy, 
45 cats had one ( n  =  24), two ( n  =  16), three ( n  =  4) 
or four ( n  =  1) surgeries prior to radiation. Two of 
these cats already developed tumour recurrence 
before radiation therapy had started, and these cats 
were therefore irradiated in the gross disease set-
ting. In one of these cats, tumour margins were 
dirty, and in the other cat, tumour margins were 
not assessable. A third cat underwent surgery after 
radiation therapy; the tumour was completely 
excised. Altogether, tumour excision was complete 
in 33/46 (72%) cases (margins were wide in 22 cats 
and clean but close in 11 cats), and incomplete ex-
cision was found in six (13%) of 46 animals. In the 
remaining ﬁ ve (11%) cases, completeness of excision 
was not assessable. 
 Of all 27 cats treated with the coarse fractionation 
protocol, 10 cats had prior surgery and were free of 
gross disease at the time of irradiation and two cats 
irradiated in the gross disease setting underwent 
surgery after radiation therapy. Of the 10 cats that 
had surgery before radiation therapy, four had one 
surgery, three had two surgeries, one had three sur-
geries and two animals had four surgeries prior to 
radiation therapy. Margins were dirty in seven of 
these 10 (70%) cats, clean but close in one (10%) 
and not assessable in two (20%) animals. In the two 
cats with surgery after radiotherapy, margins were 
wide in one cat and clean but close in the other. 
 Chemotherapy 
 Only one of the curatively treated cats received che-
motherapy. It consisted of doxorubicin and was ad-
ministered concurrently to radiation therapy. 
Altogether 13 of the 27 irradiated cats treated with a 
coarse fractionation protocol received additional 
chemotherapy. In 11 of these cats, chemotherapy 
was started together with radiation, and in the re-
maining two cats, it was started after radiation ended. 
This group comprised eight of 10 animals with no 
 Table  2.  Clinical characteristics and adjuvant therapies in cats treated with curative or coarse radiation therapy 
 RT protocol 
 Number of cats with tumour appearance 
and surgery as indicated 
 Number of cats with tumour 
margins as indicated 
 Number of cats 
with adjuvant 
chemotherapy 
Curative ( n  =  46) No visible mass 43 Wide 21 0 
Clean but close 11 1 
Dirty 6 0 
NA 5 0 
Gross disease 3  
  Surgery after RT 1 Wide 1 0 
Coarse ( n  =  27) No visible mass 10 Dirty 7 6 
Clean but close 1 1 
NA 2 1 
Gross disease 17  
  No surgery 15 NR 4 
  Surgery after RT 2 Wide 1 1 
Clean but close 1 0 
 NA, not assessable; NR, not relevant; RT, radiation therapy. 
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visible mass and ﬁ ve of 17 cats with macroscopic dis-
ease. In all cases, doxorubicin (20  mg  m  − 2 or 1  mg  kg  − 1 
administered in three sessions, except for two cats 
that received it only once and one cat that received it 
six times) was used as a single agent, except in one 
case where cyclophosphamide (250  mg  m  − 2 evenly 
distributed over 4  days) was added. The use of che-
motherapy did not cause any treatment response 
delays in those animals that were treated with both 
chemotherapy and ionizing radiation. 
 Additional therapy 
 Additional therapy was offered to all patients after 
progressive disease was observed, regardless of the 
initial treatment. In 15 curatively treated cats, it 
consisted of surgery ( n  =  7), chemotherapy ( n  =  1), 
radiation therapy ( n  =  1) or a combination of these 
treatments ( n  =  6). In six of 17 cats with macro-
scopic disease subjected to coarse fractionated 
therapy, additional therapy consisted of either a 
second round of radiation therapy ( n  =  3), ancillary 
surgery ( n  =  2) or chemotherapy ( n  =  1). Two cats 
with no visible mass treated with coarse fraction-
ation protocol received additional therapy consist-
ing of a combination of these modalities. 
 Histopathological reassessment 
 Parafﬁ n blocks from 55 of 73 cats were available for 
histopathological reassessment. In the remaining 
cases, no parafﬁ n blocks were available. The tu-
mours were classiﬁ ed as ﬁ brocytic ( n  =  25), histio-
cytic ( n  =  4) or mixed cell type ( n  =  26) in 
dependence of the predominant cellular morphol-
ogy ( Fig.  1 ). The detailed results of histological 
grading are reported in  Table  1 . For statistical anal-
ysis, 27 cats (49%) were assigned to the low-grade 
group (comprising histological grades I and II) and 
28 animals (51%) to the high-grade group (histo-
logical grade III). Multinucleated giant cells did 
not appear in histological grade I tumours and 
were detected in only six of 25 grade II tumours 
and in 20 of 28 grade III tumours. 
 Ki67 index 
 The mean number of cells counted to assess the 
Ki67 index was 1272 (range 711 – 3015). Ki67 could 
be evaluated in 52/55 cases. Three cases were ex-
cluded: in one instance, too many cells stained 
positive for CD3 and CD79alpha preventing proper 
identiﬁ cation of tumour cells for counting. And, in 
two other cases, it was not possible to count a mini-
mum of 700 cells. Of the 52 cases evaluated, 36 
were curatively treated and 16 were treated with 
coarse fractionated radiotherapy. The percentage 
of Ki67-positive cells varied between 0 and 40%, 
with a mean of 14% ( Fig.  1 ). The Ki67 index did 
not correlate with grade, neither in a continuous 
form nor after grouping using any of the cut-offs 
(10%, 20%). 
 PFI and survival 
 The median follow-up time for all animals in this 
study was 21  months. The median follow-up time 
in the curative group was 25  months, while the 
group that received coarse fractionated therapy had 
a median follow-up of 10  months. For the censored 
animals in the curative group, the median follow-
up time was 32  months, and for the cats receiving 
coarse fractionated therapy, it was 12  months. 
 The main data related to the PFI are summa-
rized in  Tables  3 and 4 and in  Figs  2 and 3 . Cura-
tively treated patients ( n  =  46) had a median PFI 
of 37  months (95% conﬁ dence intervals [CI] 
19 – 56  months). In this group, 63% ( n  =  29) of the 
animals were progression free after 1  year (95% CI 
49 – 78%) and 60% ( n  =  28) after 2  years (95% CI 
45 – 75%). Fifty percent ( n  =  23) of the cats were tu-
mour free at the time of data analysis and were 
therefore censored. The median PFI of all cats re-
ceiving coarse fractionated therapy ( n  =  27) was 
10  months (95% CI 8 – 15  months). Seven of these 
27 patients (26%) were censored. Cats with no vis-
ible mass receiving coarse fractionated therapy 
( n  =  10) had a signiﬁ cantly longer median PFI 
(20  months, 95% CI 9 – 30  months) than those with 
macroscopic disease ( n  =  17, 4  months, 95% CI 
2 – 5  months;  P  =  0.01). In the curatively treated 
group, the Ki67 index had no signiﬁ cant impact on 
PFI with any of the predictors examined. In the 
group treated with coarse fractionated radiotherapy, 
the Ki67 index showed no signiﬁ cant inﬂ uence on 
PFI when examined in a continuous form, a ten-
dency towards a longer PFI in cases with more than 
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10% positive tumour cells ( P  =  0.0815) and a sig-
niﬁ cantly longer PFI in cases with more than 20% 
positive tumour cells ( P  =  0.015, multiple Cox re-
gression analysis). Differentiation of no visible 
mass/macroscopic disease was the only other pre-
dictor of PFI for cats with coarse fractionation sug-
gested by the backward Cox regression ( P  =  0.002). 
 The main data related to survival are summa-
rized in  Tables  3 and 4 and in  Figs  4 – 6 . Curatively 
treated cats ( n  =  46) displayed a median survival 
time of 43  months (95% CI 40 – 46  months). Eighty-
six percent ( n  =  39) of these animals were alive after 
1  year (95% CI 76 – 96%), 71% ( n  =  33) after 2  years 
(95% CI 56 – 85%) and 68% ( n  =  31) after 3  years 
(95% CI 53 – 83%). Twenty-eight of the 46 (61%) 
cats in this group were still alive at the time of data 
analysis or dead because of tumour-unrelated dis-
ease and were therefore censored. The median sur-
vival time for cats undergoing coarse fractionated 
therapy ( n  =  27) was 24  months (95% CI 4 – 43 
months). Fifty-nine percent ( n  =  17) of these animals 
were alive after 1  year (95% CI 39 – 79%). Of the 27 
cats treated with coarse fractionated radiotherapy, 
nine animals (33%) were censored. Patients with 
no visible mass receiving coarse fractionated therapy 
( n  =  10) lived signiﬁ cantly longer (median survival 
30  months; 95% CI 21 – 40  months) than those with 
macroscopic disease ( n  =  17, median survival 
7  months; 95% CI 5 – 10  months;  P  =  0.025). How-
ever, survival in cats with macroscopic disease was 
signiﬁ cantly prolonged when adjuvant chemother-
apy was used ( n  =  5, median survival 29  months, 
95% CI 11 – 46  months;  P  =  0.04). In cats with no 
visible mass, additional beneﬁ t of chemotherapy 
over coarse fractionated radiotherapy alone could 
not be evaluated statistically. The Ki67 index did 
not correlate in any of the forms examined with 
survival neither in curatively treated patients nor in 
animals receiving coarse fractionated therapy. 
 Tumour margins had no signiﬁ cant impact on 
outcome. In curatively treated cats, there was no 
signiﬁ cant difference in outcome neither between 
cats with wide ( n  =  22) and clean but close ( n  =  11) 
margins nor between cats with complete ( n  =  33) 
and incomplete ( n  =  6) excisions. The outcome in 
the cats with wide excisions ( n  =  22, including the 
cat with surgery after radiation therapy) and in the 
cats with clean but close and dirty margins ( n  =  11 
and  n  =  6, respectively) did not signiﬁ cantly differ 
either. When the outcome in the curative group 
was compared with a group where  ‘ non-conﬁ rming ’ 
cats as the cat that received chemotherapy ( n  =  1), 
the cats with dirty margins ( n  =  6), those with gross 
disease ( n  =  3) and those with non-assessable mar-
gins ( n  =  5) were removed, the 95% CI for median 
PFI and survival time overlapped between these 
two groups. This suggests that no signs of bias were 
introduced by these  ‘ non-conﬁ rming ’ cats. This 
was also true when the outcome in the curative 
group was compared with another group where 
different  ‘ non-conﬁ rming ’ cats were removed in-
cluding the cat that received chemotherapy ( n  =  1), 
the cats with gross disease ( n  =  3), the cats with 
non-assessable margins ( n  =  5) and those with wide 
excisions ( n  =  21). 
 No signiﬁ cant difference was observed when 
comparing the outcome in cats with dirty margins 
in the curative group ( n  =  6) versus in the coarse 
fractionated therapy group ( n  =  7). Low animal 
 Table  3.  Median PFI and survival in months (95% CI) for cats 
with vaccine-associated sarcoma split into a curative 
and a coarse fractionated radiotherapy group ( Figs  2 and 4 ) 
 
 Curative 
radiotherapy 
( n  =  46) 
 Coarse fractionated 
( n  =  27) 
PFI  P  =  0.0004 37 (19 – 56) 10 (8 – 15) 
Survival  P  =  0.0003 43 (40 – 46) 24 (4 – 43) 
 Table  4.  Median PFI and survival in months (95% CI) for cats with vaccine-associated sarcoma receiving coarse fractionated 
radiotherapy ( Figs  3, 5 and 6 ) 
 
 No visible mass 
( n  =  10) 
 Gross disease 
( n  =  17)  P  value 
 Gross disease  −  chemo 
( n  =  12) 
 Gross disease  +  chemo 
( n  =  5)  P  value 
PFI 20 (9 – 30) 4 (2 – 5) 0.01 3 (2 – 4) 12 (0 – 30)  0.189
Survival 30 (21 – 40) 7 (5 – 10) 0.025 5 (3 – 7) 29 (11 – 46)  0.04 
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numbers prevented statistical analysis of the mar-
gin status in regard to outcome in cats with no visi-
ble mass treated with the coarse fractionation 
protocol. The number of previous surgeries did 
not inﬂ uence the outcome in curatively treated 
cats. In contrast, an increasing number of previous 
surgeries were signiﬁ cantly associated with a 
shorter survival time in cats undergoing coarse 
fractionated radiotherapy (coeff  =  0.41,  P  =  0.03). 
Additional therapy did not inﬂ uence survival in 
the curatively treated cats as indicated by a lack of 
difference between outcomes in cats with and with-
out additional therapy. In contrast, additional 
therapy resulted in signiﬁ cantly prolonged survival 
in cats subjected to coarse fractionated therapy 
( n  =  8,  P  =  0.001). 
 None of the further demographical, clinical and 
histological parameters tested correlated with 
outcome. 
 Discussion 
 In this study, cats treated with a curative intent had 
a median survival of 43  months and a median PFI 
of 37  months. The latter variable was longer in our 
collective than in two previous studies (14  months, 
22  months) 18,19 where radiation therapy was also 
applied after surgery. In a further previous study 
  
 Figure  2.  PFI for 73 cats with vaccine-associated sarcoma 
split into a curative and coarse fractionated radiotherapy 
group (P  =  0.0004). 
  
 Figure  3.  PFI for 27 cats with vaccine-associated sarcoma 
receiving coarse fractionated radiotherapy split into patients 
with no visible mass and with macroscopic disease (P  =  0.01). 
  
 Figure  4.  Survival for 73 cats with vaccine-associated 
sarcoma split into a curative and a coarse fractionated 
radiotherapy group (P  =  0.0003). 
 Figure  5.  Survival for 27 cats with vaccine-associated 
sarcoma receiving coarse fractionated radiotherapy split 
into patients with no visible mass and with macroscopic 
disease (P  =  0.025). 
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where radiation therapy was applied before sur-
gery, the PFI was shorter as well (20  months). 21 
Outcomes in our series were achieved with total 
doses of 45 or 48  Gy, which is considerably lower 
than those reported in the former two above-
 mentioned studies (52 or 57  Gy). 18,19 This favourable 
outcome might be because of the large proportion 
of cats with complete surgical excision. However, 
in our study, there was no signiﬁ cant difference in 
curatively treated cats between completely and in-
completely excised tumours regarding survival 
and PFI. In contrast, previous investigations have 
shown that cats with complete surgical excision 
have a signiﬁ cant better outcome than those with 
incomplete excision. 15,21,47 A factor complicating 
the assessment of the prognostic signiﬁ cance of 
the tumour margins is that criteria for complete 
and incomplete excision were not deﬁ ned 15,47 or 
differed 21 from those of the present study. Al-
though the data cannot be directly compared be-
cause of basic differences in the study designs, 
results of the present study support the notion that 
adding curative radiation after surgery improves 
outcome. 
 In this study, cats treated with a coarse fraction-
ation protocol had a median survival of 24  months 
and a PFI of 10  months. These times are somehow 
surprisingly long. To our knowledge, a coarse frac-
tionation protocol has never before been reported 
for use in cats with vaccine-associated sarcoma. In 
our practice, it turned out to meet a need of the 
owners because of its reduced costs and time re-
quirements in contrast to the curative protocol. It 
was primarily recommended for the cats with in-
complete excision because of their possible higher 
likelihood of recurrence and poor outcome. 15,21,47 
The cats with no visible mass in this group had a 
median survival of 30  months and a median PFI of 
20  months. In a previous study, the median time to 
ﬁ rst event for pre-operative curative radiation fol-
lowed by an incomplete excision was 292  days 
(10  months). 21 In another study, Bregazzi  et al.  ir-
radiated microscopic remnants at the surgical site 
with curative intent and administered doxorubicin 
afterwards. The animals in that report reached a 
median PFI of 661  days (22  months), 19 which is 
similar to the ﬁ gure found in our study (20  months). 
However, a smaller number of fractions and a 
lesser total dose were used in our patients com-
pared with the Bregazzi ’ s study. In both studies 
(ours and Bregazzi ’ s), radiation therapy was ap-
plied after surgery. Therefore, although the overall 
number of animals used in this study was low, our 
data suggest that a postsurgical coarse fractionation 
protocol may have a role in the management of 
cats with no visible mass and warrants further 
prospective evaluation. 
 In cats with gross disease and treated with a 
coarse fractionation protocol, adjuvant chemo-
therapy had a positive effect on survival (the me-
dian survival increased from 5  months in cats 
without chemotherapy,  n  =  12, to 29  months in 
cats receiving chemotherapy,  n  =  5,  P  =  0.04) but 
not on PFI. This survival data must be interpreted 
cautiously because of a possible inﬂ uence of addi-
tional therapy that was applied after progressive 
disease. In addition, although chemotherapy was 
recommended for all cats receiving a coarse frac-
tionation protocol, in this retrospective analysis, 
it was not possible to determine how far clinical 
factors with inﬂ uence on outcome (e.g. clinical 
signs or tumour size) played a role in the owner ’ s 
decision to apply this treatment. For these rea-
sons and as the number of patients was small, 
these results need to be conﬁ rmed with a higher 
number of cats. Previous studies showed either 
no 47 or only a modest 16 effect of chemotherapy 
alone in animals with non-resectable tumours. In 
the latter investigation, approximately 50% of the 
  
 Figure  6.  Survival for 17 cats with gross disease receiving 
coarse fractionated radiotherapy with or without chemo-
therapy (P  =  0.04). 
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cats responded to chemotherapy and showed a 
median survival of 242  days (8  months). In many 
cats with macroscopic disease, coarse fractionated 
therapy implies a palliative intent. The primary 
goal of palliation is not to provide long-term or 
deﬁ nitive tumour control but to induce pain re-
lief or to reduce dysfunction associated with the 
tumour in patients in which other factors such as 
advanced metastatic disease or a severe concur-
rent disease are likely to lead to their demise. 55 
However, as suggested from the current study, a 
coarse fractionation protocol in combination 
with chemotherapy may improve outcome, thus 
providing an additional therapeutic option for 
such cats. The appropriate treatment (either 
coarse fractionation radiation protocol or che-
motherapy or both) should be chosen individu-
ally from case to case. In conclusion, our data 
suggest that a coarse fractionation protocol also 
should have a place in the management of macro-
scopic disease. 
 An important restriction applies to the survival 
data in general because of the retrospective charac-
ter of this study. In fact, in many cases, the cause of 
death was assessed by local veterinarians or by the 
owners themselves. Therefore, survival informa-
tion must be interpreted cautiously. Similarly, the 
apparent lack of development of metastases during 
or after therapy in our collective may be a conse-
quence of the lack of necropsy data. An absence of 
metastases is consistent with previous studies 
where vaccine-associated sarcomas were mainly lo-
cally invasive with no metastases or with low meta-
static rates. 19,48 In more recent reports, however, 
metastatic rates of 12 18 and 21% 21,49 have been in-
dicated. In a new study by Romanelli  et al.  in 2008, 
cats with histological grade III tumours were sig-
niﬁ cantly more likely to develop metastasis than 
those with grade I and II tumours. 49 
 In this study, neither histological grading nor 
its components taken individually were predictive 
of survival or PFI of cats diagnosed with vaccine-
associated sarcomas. This is in contrast with hu-
man soft tissue sarcomas 50 – 52 where histological 
grading is the most important prognostic factor. 
A previous study in cats where the same grading 
system was used also failed to demonstrate such a 
correlation in vaccine-associated sarcomas. 43 This 
was also the case in a further study by Davidson  et 
al. , 15 who however used a different grading 
scheme. Our study conﬁ rms the ﬁ ndings by Couto 
 et al. 43 that multinucleated giant cells do not 
occur in grade I vaccine-associated sarcomas. 
However, and contrary to what is described in 
human patients with soft tissue sarcomas, 53,54 the 
presence of multinucleated giant cells does not 
appear to be useful to estimate prognosis in this 
tumour type. 
 In our study, Ki67 index had no impact on sur-
vival in cats treated neither with a curative nor 
with a coarse fractionation protocol. However, 
when the 20% cut-off was used in the multivari-
ate analysis for cats undergoing coarse fraction-
ated radiotherapy, the PFI was signiﬁ cantly 
prolonged ( P  =  0.015). Because of the heterogene-
ity of treatments (no visible mass versus macro-
scopic disease / with versus without chemotherapy) 
in this group of patients, these results should be 
evaluated critically. In addition, it cannot be 
completely ruled out that our selection method 
for appropriate cores for Ki67 counts, which 
tended to exclude tumour regions with strong in-
ﬂ ammation constituted a bias. However, a previ-
ous study has shown no differences in the 
Ki67-labelling index between samples from the 
centre of the tumours and the periphery. 43 Most 
inﬂ ammatory inﬁ ltrates are found in the latter. In 
conclusion, the results of the Ki67 evaluation 
were rather unexpected, and this topic will require 
further studies. 
 In summary, the results of the present study in-
dicate that in vaccine-associated sarcomas, the 
combination of surgery and subsequent radiation 
therapy is an effective option. Curatively treated 
cats displayed a median survival time of 43  months, 
while 86% of the cats were alive after 1  year (95% 
CI 76 – 96%), 71% after 2  years (95% CI 56 – 85%) 
and 68% after 3  years (95% CI 53 – 83%), and their 
median PFI was 37  months. A coarse fractionation 
protocol also appears to have a place in the man-
agement of vaccine-associated sarcomas. In this 
setting, factors predictive of a better outcome in 
our study include no visible mass as opposed to 
macroscopic disease, additional chemotherapy 
in cats with gross disease and a smaller number of 
surgeries performed before radiation therapy. 
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The predictive value of the Ki67 index needs to 
be further clarified in feline vaccine-associated 
sarcomas. 
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